| |
No CAD (n = 42, 34.1%)
|
One-vessel CAD (N = 21, 17.1%)
|
Two-vessel CAD (N = 24, 19.5%)
|
Three-vessel CAD (n = 36, 29.3%)
|
p
|
|---|
|
Age (years)
|
62.5 ± 10.8
|
63.9 ± 9.2
|
65.7 ± 9.1
|
66.7 ± 7.8
|
0.250
|
|
Male gender
|
17 (40.5%)
|
14 (66.7%)
|
20 (83.3%)
|
27 (75.0%)
|
< 0.001
|
|
BMI (kg/m2)
|
28.0 ± 4.3
|
28.2 ± 3.9
|
29.2 ± 3.9
|
28.6 ± 5.0
|
0.748
|
|
eGFR (ml/min/1.73 m2)
|
77.7 ± 20.6
|
78.2 ± 13.8
|
72.7 ± 17.3
|
73.3 ± 15.5
|
0.491
|
|
ABI
|
1.1 ± 0.1
|
1.0 ± 0.1
|
1.1 ± 0.1
|
1.0 ± 0.1
|
0.170
|
|
Active smoking
|
8 (19.0%)
|
7 (33.3%)
|
4 (16.7%)
|
3 (8.33%)
|
0.071
|
|
Arterial hypertension
|
26 (61.9%)
|
18 (85.7%)
|
24 (100%)
|
30 (83.3%)
|
0.110
|
|
Diabetes
|
6 (14.3%)
|
3 (14.3%)
|
5 (20.8%)
|
13 (36.1%)
|
0.140
|
|
MAP (mmHg)
|
97.3 ± 11.6
|
88.0 ± 9.2
|
92.1 ± 9.7
|
96.0 ± 18.6
|
0.043
|
|
Dyslipidemia
|
14 (33.3%)
|
16 (76.2%)
|
18 (75.0%)
|
21 (58.3%)
|
0.057
|
|
SEVR (%)
|
159.5 ± 32.9
|
181.0 ± 35.2
|
166.8 ± 27.8
|
158.1 ± 31.5
|
0.048
|
|
cfPWV (m/s)
|
10.5 ± 3.2
|
9.6 ± 2.1
|
10.4 ± 2.4
|
10.7 ± 2.7
|
0.487
|
|
AIx (%)
|
28.5 ± 11.1
|
30.3 ± 8.4
|
28.4 ± 8.8
|
28.7 ± 10.6
|
0.902
|
|
AIx@75
|
26.9 ± 12.2
|
25.6 ± 8.9
|
25.5 ± 7.5
|
25.8 ± 8.9
|
0.932
|
|
AP (mmHg)
|
14.2 ± 7.4
|
13.3 ± 5.6
|
14.9 ± 7.1
|
16.6 ± 11.0
|
0.469
|
|
ED (ms)
|
34.7 ± 3.8
|
32.5 ± 3.6
|
33.3 ± 4.0
|
34.1 ± 4.6
|
0.187
|
|
PP (mmHg)
|
47.0 ± 14.7
|
43.1 ± 13.5
|
48.4 ± 10.7
|
50.7 ± 18.1
|
0.293
|
|
HR (beats/minute)
|
70.1 ± 10.5
|
65.1 ± 8.8
|
69.0 ± 12.4
|
69.0 ± 12.4
|
0.390
|
- For all tests, a p-value of < 0.05 was statistically significant which are indicated in bold
- CAD coronary artery disease, BMI body mass index, eGFR estimated glomerular filtration rate, ABI ankle-brachial index, MAP mean arterial pressure, SEVR subendocardial viability ratio, cfPWV carotid-femoral pulse wave velocity, Aix augmentation index, AIx@75 augmentation index adjusted for heart rate 75/minute, AP augmentation pressure, ED ejection duration, PP pulse pressure, HR heart rate
